Summary
A double-blind crossover trial compared tizanidine with baclofen in 36 patients with spasticity. Tizanidine appeared to reduce lower limb spasticity more effectively and to have fewer side effects, but no statistically significant differences emerged when the two drugs were compared. An additional open study of tizanidine confirmed the beneficial action in a selected minority of patients with spasticity. This drug may have an important role in the management of spasticity, but further studies are required.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ashworth B (1964) Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192: 540–542
Hassan N, McLellan DL (1980) Double blind comparison of single doses of DS 103–282, baclofen and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry 43: 1132–1136
Kurtzke JF (1961) On the evaluation of disability in multiple sclerosis. Neurology (Minneap) 11: 686–694
Pedersen E (1965) A rating system for neurological impairment in multiple sclerosis. Acta Neurol Scand 41 (Suppl 13): 557
Ringwald E, Campion SJ, Gerstenbrand F, Lorincz A, Lorincz P, Ludin HP (1977) Klinische Erfahrungen mit einem neuartigen Myotonolytikum (DS 103–282 Sandoz). Nervenarzt 48: 355–358
Rinne UK (1980) Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res 28: 827–836
Sayers AC, Burchi HR, Eichenberger E (1980). The pharmacology of DS 103–282, a novel myotonolytic agent. Arzneim Forsch Drug Research 30: 793–803
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Newman, P.M., Nogues, M., Newman, P.K. et al. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 23, 31–35 (1982). https://doi.org/10.1007/BF01061374
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01061374